Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty To assess the efficacy of Triptorelin 11.25 mg pamoate with respect to the proportion of children with suppressed LH response (LH < or = 3 UI/l) to GnRH test performed 3 months (M3) after injection wi...

• Country None
• organs None
• Specialty None

A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in patients with prostate cancer Part A: To determine the proportion of patients remaining medically castrated (serum testosterone level < 50 ng/dL) at Day 240 following two SC administrations of a 4-month sustained-release (SR) form...

• Country None
• organs None
• Specialty None

Effect of oral EGb 761® on Brain Glucose Metabolism in Three Groups of Elderly with Memory Complaint, mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, randomised, double-blind, parallel groups, placebo-controlled study To evaluate the effect of four weeks treatment with EGb761® in comparison to placebo in three groups of elderly : MC, AD and CNE. The primary endpoint will be the change in brain glucose metabolism ...

• Country None
• organs None
• Specialty None

A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cancer To evaluate the pharmacodynamic profile of a 6-month sustained-release formulation of triptorelin administered as two simultaneous subcutaneous microimplant injections (2x6 mg) by measuring serum test...

• Country None
• organs None
• Specialty None

FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIOUS PUBERTY To assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.

• Country None
• organs None
• Specialty None

A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients To investigate the pharmacodynamics (PD) of BIM 23A760, administered by single subcutaneous (s.c.) injection to acromegalic patients.

• Country None
• organs None
• Specialty None

PHASE III, MULTICENTRE, OPEN STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILES OF THE CO-ADMINISTRATION OF LANREOTIDE AUTOGEL 120 MG (ADMINISTERED VIA DEEP SUBCUTANEOUS INJECTIONS EVERY 28 DAYS) AND PEGVISOMANT 40 TO 120 MG PER WEEK (ADMINISTERED VIA SUBCUTANEOUS ROUTE ONCE OR TWICE A WEEK) IN ACROMEGALIC PATIENTS FAILING TO RESPOND TO LANREOTIDE AUTOGEL 120 MG ALONE To assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep subcutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via su...

• Country None
• organs None
• Specialty None

Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.

• Country None
• organs None
• Specialty None

Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with intestinal obstruction due to peritoneal carcinomatosis in inoperable patients The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with periton...

• Country None
• organs None
• Specialty None

AN EXPLORATORY, OPEN, TWO-ARM, MATCH-CONTROL, RANDOMISED AND STRATIFIED PILOT PHASE II STUDY ASSESSING THE PREVENTION OF THE ADVERSE EFFECTS OF LONG-TERM HIGH-DOSE GLUCOCORTICOID THERAPY BY GROWTH HORMONE (NutropinAqTM) ADMINISTERED BY SUB-CUTANEOUS ROUTE IN CHILDREN WITH CHRONIC DISEASE The primary objective of the study is to determine whether the administration of growth hormone will result in the prevention/reduction of adverse effects induced by long-term high-dose glucocorticoid...

• Country None
• organs None
• Specialty None